Tag: hematology

Evidence Rating Level: 2 (Good)  1. Combination therapy of Ibrutinib and Venetoclax may be successful first-line treatments for patients with Chronic Lymphocytic Leukemia (CLL) who are currently not undergoing treatment  2. This combination therapy had a 3-year progression free survival (PFS) of 93% in first line treatment of CLL  The evolution and...